People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardurion Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $431.7M | $2.8B | 2024 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Translate Bio, Inc. | — | Biotechnology | Series C | $98.5M | $1.9B | 2016 |
| Proclara Biosciences, Inc. | — | Biotechnology | Series C | $76.8M | $283.6M | 2016 |
| Avila Therapeutics Inc | — | Biotechnology | Series B | $45.0M | $893.0M | 2009 |
| SpringWorks Therapeutics, LLC | — | Pharma | Series A | $12.8M | $396.9M | 2017 |
| Stromedix Inc | — | Pharmaceuticals | Seed | $2.0M | $76.1M | 2011 |
Daniel Lynch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Lynch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Vicki Sato | 2 | 6 |
| Carl Gordon | 1 | 24 |
| DAVID GARDNER | 1 | 20 |
| Peter Barrett | 1 | 18 |
| Michael Ross | 1 | 18 |
| Jean-Francois Formela | 1 | 17 |
| Amir Nashat | 1 | 14 |
| Robert Weisskoff | 1 | 12 |
| Edward Mathers | 1 | 12 |
| Bruce Booth | 1 | 12 |
| Brian Gallagher | 1 | 11 |
| Amy Schulman | 1 | 11 |
| Stephen Squinto | 1 | 8 |
| Stephen Kraus | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| David Grayzel | 1 | 6 |
| Michael Gilman | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Andrew Hack | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.